KGM™KeratinocyteGrowthMediumhasbeenoptimizedfortheproliferationofkeratinocytesinaserum-freeenvironment.KGM™-CDChemicallyDefinedKeratinocyteGrowthMediumwasdesignedasaserum-free,xeno-free,chemicallydefinedcellculturemediumtosupporttheisolation,growthandproliferationofprimaryhumankeratinocytesinculture.
DidyouknowourcustomershaveusedKGMTMMediaalsotocultureimmortalizedcornealepithelialcells?CheckoutJolly,et.al. publicationthatprovidessomeguidelinestodothis.
KGM™-CDistheonlymediumofitskindonthemarkettodayandcanbeusedforavarietyofapplicationsassociatedwithskinresearch,woundhealinganddermaldisorders.TheKBM™-CDBasalMedium,KGM™-CDSingleQuots™KitandtheKGM™-CDBulletKit™allowcustomersthesameflexibilityasotherClonetics™MediaProducts.
KGM™-CDisalsoabletosupportgrowthandproliferationofbothadultandneonatalprimaryhumandermalkeratinocytesascomparedtoournon-definedKGM™-2Medium-determinedbytotalpopulationdoublings(totalPDLs).Therewasexcellentlot-to-lotconsistencyforeachmediatestedwheretheKGM™-CDMediumsupportednearly25populationdoublingsinourtestingwhilestillmaintainingnormalkeratinocytecharacteristics.
ThisKGM™-CDmediasystemisacomplete,optimizedsystemforisolatingandgrowingprimaryhumankeratinocytes.Note:Coatingplateswithfibronectinorothernon-animalderivedmatrixmaterialisnecessaryforsuccessfulkeratinocyteisolationswithKGM™-CDmedium.
Note:AntibioticsarenotincludedwiththeSingleQuots™Kit(CC-4456)andmustbepurchasedseparately.
Formoreinformationonthediscontinuationofcertainkeratinocytesproducts,clickhere
龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach,公司经营范围包括:生物技术开发服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);生物技术推广服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);生物技术咨询、交流服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);生物技术转让服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);医学研究和试验发展(人体干细胞、基因诊断与治疗技术除外);药品研发(人体干细胞、基因诊断与治疗技术除外);货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易(涉及外资准入特别管理规定和许可审批的商品除外);生物药品制造;化学药品原料药制造;化学药品制剂制造等。